Viewing Study NCT02370706

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 4:00 PM
Ignite Modification Date: 2026-03-01 @ 10:49 PM
Study NCT ID: NCT02370706
Status: COMPLETED
Last Update Posted: 2022-02-09
First Post: 2015-02-06
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Myelofibrosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PIM447 View
None LGH447 View
None PIM inhibitor View
None LEE011 View
None CDK 4/6 inhibitor View
None ruxolitinib View
None INC424 View
None Jakavi® View
None Jakafi® View
None INCB18424 View
None JAK inhibitor View
None myelofibrosis View
None PMF View
None PPV-MF View
None PET-MF View